Quince Therapeutics/$QNCX
14:30
10:10
05:45
01:25
21:00
1D1W1MYTD1Y5YMAX
About Quince Therapeutics
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Ticker
$QNCX
Sector
Primary listing
Employees
36
Headquarters
Website
QNCX Metrics
BasicAdvanced
$5.5M
-
-$1.21
1.04
-
Price and volume
Market cap
$5.5M
Beta
1.04
52-week high
$4.55
52-week low
$0.10
Average daily volume
113M
Financial strength
Current ratio
1.121
Quick ratio
1.048
Long term debt to equity
33.9
Total debt to equity
1,699.056
Interest coverage (TTM)
-45.74%
Profitability
EBITDA (TTM)
-41.683
Effective tax rate (TTM)
-0.13%
Management effectiveness
Return on assets (TTM)
-22.10%
Return on equity (TTM)
-247.78%
Valuation
Price to book
5.08
Price to tangible book (TTM)
9.03
Price to free cash flow (TTM)
-0.119
Free cash flow yield (TTM)
-837.24%
Free cash flow per share (TTM)
-0.827
Growth
Earnings per share change (TTM)
-3.29%
3-year earnings per share growth (CAGR)
-17.69%
QNCX News
AllArticlesVideos
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks
Benzinga·3 weeks ago
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Business Wire·3 weeks ago
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Quince Therapeutics stock?
Quince Therapeutics (QNCX) has a market cap of $5.5M as of March 03, 2026.
What is the P/E ratio for Quince Therapeutics stock?
The price to earnings (P/E) ratio for Quince Therapeutics (QNCX) stock is 0 as of March 03, 2026.
Does Quince Therapeutics stock pay dividends?
No, Quince Therapeutics (QNCX) stock does not pay dividends to its shareholders as of March 03, 2026.
When is the next Quince Therapeutics dividend payment date?
Quince Therapeutics (QNCX) stock does not pay dividends to its shareholders.
What is the beta indicator for Quince Therapeutics?
Quince Therapeutics (QNCX) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.